Morgan Stanley
NRIX icon

Morgan Stanley’s Nurix Therapeutics NRIX Stock Holding History

Morgan Stanley’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$76.4M Buy
4,931,999
+50,930
+1% +$844K ﹤0.01% 1669
2025
Q4 		$92.6M Buy
4,881,069
+2,620,323
+116% +$37.6M 0.01% 1521
2025
Q3 		$20.9M Buy
2,260,746
+93,625
+4% +$972K ﹤0.01% 2855
2025
Q2 		$24.7M Buy
2,167,121
+700,261
+48% +$7.57M ﹤0.01% 2593
2025
Q1 		$17.4M Sell
1,466,860
-98,106
-6% -$1.64M ﹤0.01% 2831
2024
Q4 		$29.5M Sell
1,564,966
-313,598
-17% -$7.19M ﹤0.01% 2355
2024
Q3 		$42.2M Sell
1,878,564
-111,136
-6% -$2.52M ﹤0.01% 1993
2024
Q2 		$41.5M Sell
1,989,700
-541,099
-21% -$8.43M ﹤0.01% 1933
2024
Q1 		$37.2M Sell
2,530,799
-3,739,275
-60% -$40.2M ﹤0.01% 2044
2023
Q4 		$64.7M Buy
6,270,074
+6,016,661
+2,374% +$41.2M ﹤0.01% 2179
2023
Q3 		$1.99M Buy
253,413
+44,316
+21% +$405K ﹤0.01% 4403
2023
Q2 		$2.09M Sell
209,097
-43,815
-17% -$447K ﹤0.01% 4395
2023
Q1 		$2.25M Sell
252,912
-147,510
-37% -$1.54M ﹤0.01% 4385
2022
Q4 		$4.4M Sell
400,422
-80,120
-17% -$966K ﹤0.01% 3866
2022
Q3 		$6.26M Sell
480,542
-101,563
-17% -$1.61M ﹤0.01% 3478
2022
Q2 		$7.38M Sell
582,105
-98,754
-15% -$1.12M ﹤0.01% 3393
2022
Q1 		$9.54M Buy
680,859
+594,538
+689% +$10.6M ﹤0.01% 2959
2021
Q4 		$2.5M Sell
86,321
-53,252
-38% -$1.61M ﹤0.01% 4400
2021
Q3 		$4.18M Sell
139,573
-303,465
-68% -$9.37M ﹤0.01% 3923
2021
Q2 		$11.8M Buy
443,038
+348,995
+371% +$10.2M ﹤0.01% 2794
2021
Q1 		$2.92M Buy
94,043
+85,246
+969% +$3.23M ﹤0.01% 3951
2020
Q4 		$289K Buy
8,797
+7,069
+409% +$234K ﹤0.01% 5393
2020
Q3 		$60K Buy
+1,728
New +$43.5K ﹤0.01% 5657

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Morgan Stanley's NRIX Position: Q1 2026 in Review

Morgan Stanley increased its Nurix Therapeutics (NRIX) stake by 1% in Q1 2026, buying an estimated $844K and bringing the position to 4,931,999 shares worth $76.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1669.

Morgan Stanley first reported a position in NRIX in Q3 2020 and has held it in 23 quarters since. The position peaked at $92.6M in Q4 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Morgan Stanley held 4,931,999 shares of Nurix Therapeutics worth $76.4M as of Q1 2026.
  • Morgan Stanley bought 50,930 Nurix Therapeutics shares in Q1 2026, an estimated $844K.
  • Nurix Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #1669 holding.
  • Morgan Stanley first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • Morgan Stanley's Nurix Therapeutics position peaked at $92.6M in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.